JPRN-UMIN000018594已完成1 期
Clinical Study of Therapeutic Angiogenesis Using Hypoxic Preconditioned Peripheral Blood Mononuclear Cells - Clinical Study of Therapeutic Angiogenesis Using Hypoxic preconditioned PBMNCs
Yamaguchi University Graduate School of Medicine Department of Surgery and Clinical Science0 个研究点目标入组 7 人开始时间: 2015年8月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients suffering from bacterial infections such as treponema palladium, chlamydia, gonorrhea and tuberculosis. 2. Patients suffering from infections such as hepatitis B and C viruses, human immunodeficiency virus, human T lymphotropic virus type 1 and parvovirus B19. 3. Patients with sepsis or suspected with. 4. Patients with malignant neoplasm or history of malignant neoplasm treatmented within five years. 5. Patients with serious endocrine disorders such as uncontrolled thyroid disfunction. 6. Patients with blood disorders except for chronic kidney disease. 7. Patients with liver disease with Child-Pugh classification B or more. 8. Patients with transmissible spongiform encephalopathy or suspected with. 9. Patients with dementia with a a revised version Hasegawa dementia scale score smaller than 4. 10. Patient determined to be ineligible for this clinical study by research attending physician.
研究者
相似试验
未知
不适用
Multicenter trial of therapeutic angiogenesis in patients with intractable vasculitisJPRN-UMIN000000939Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine40
招募中
1 期
ICS-001-1CLTI (ASO or Buerger's disease) with refractory ulcer refractory to existing therapyJPRN-jRCT2052230115Kenichi Yamahara6
招募中
不适用
A new treatment for skin ulcers associated with systemic sclerosis using the ability of own bone marrow cells to regenerate blood vesselsSystemic sclerosis, Vasculopathy, Skin ulcer, Raynaud's phenomenonSystemic sclerosisJPRN-jRCTb032210204Yoshimi Ryusuke12
进行中（未招募）
不适用
Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within theSwedish Association of Breast Oncologists SABO-2010-01Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022065-10-SESahlgrenska University Hospital
已完成
1 期
Clinical trial of new therapeutic angiogenesis for peripheral artery diseaseArteriosclerosis obliterans Buerger's diseaseJPRN-UMIN000005277Kyoto Prefectural University of Medicine10